Industries > Pharma > Top 50 Gastrointestinal Therapeutic Companies 2020

Top 50 Gastrointestinal Therapeutic Companies 2020

GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies

PUBLISHED: 04 October 2019
PAGES: 263
PRODUCT CODE: PHA0528
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA0528 Categories: , Tags: , , ,

The gastrointestinal (GI) therapeutics industry is on the rise; growing to reach $68,237.0m by 2028. This growth stems from rising prevalence of GI disorders. Moreover, the increase in R&D has been a priority of the big pharma companies to infuse the drug pipelines with a new set of candidates with a high potential of reaching the clinical stage. However, the pricing pressure due to rising competition has hampered the market growth. On the contrary, the expiry of high-profile patents, which will carve the path for the launch of generic drugs in the market can provide growth opportunities to the other players in the market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 263-page report you will receive 116 charts– all unavailable elsewhere.

The 263-page report provides clear detailed insight into the leading 50 gastrointestinal therapeutic companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Our study discusses the selected leading companies that are the major players in the gastrointestinal drugs market:
• Abbott
• AbbVie
• Alexion Pharmaceuticals
• Allergan
• ANI Pharmaceuticals, Inc.
• AstraZeneca
• Bayer AG
• Biogen
• Eisai Co., Ltd.
• Eli Lilly
• Evoke Pharma
• GlaxoSmithKline
• Intercept Pharmaceuticals
• Ironwood Pharmaceuticals
• Janssen Pharmaceutica
• Kyowa Hakko Kirin Co. Ltd.
• Mallinckrodt plc
• Pfizer
• Synergy Pharmaceuticals Inc.
• Takeda
• Cadila Healthcare Ltd.
• Novartis AG
• Shire
• Merck & Co., Inc.
• Lexicon Pharmaceuticals, Inc.
• Sanofi
• ETX Pharma, Inc.
• Theravance Biopharma, Inc.
• Other companies

Top 50 Gastrointestinal Therapeutic Companies 2020

• This report also discusses factors that drive and restrain the market, as well as opportunities in the gastrointestinal therapeutic market.

Visiongain’s study is intended for anyone requiring commercial analyses for the leading 50 gastrointestinal therapeutic companies. You find data, trends and predictions.

Buy our report today Top 50 Gastrointestinal Therapeutic Companies 2020: GlaxoSmithKline, Abbott, Allergan, Eli Lilly, Evoke Pharma, Other Companies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Top 50 Gastrointestinal Therapeutic Companies 2020


Download sample pages

Complete the form below to download your free sample pages for Top 50 Gastrointestinal Therapeutic Companies 2020


Latest Pharma news

Visiongain Publishes Generic Drugs Market Report 2020-2030

The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

03 July 2020

READ

Visiongain publishes Clinical Workflow Solutions Market Report 2020-2030

Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

03 July 2020

READ

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

READ

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

READ

Categories

Category